POTTER MYRTLE S sold $204K of GH
POTTER MYRTLE S sold 1,556 shares of Guardant Health, Inc. (GH) at $131.16 ($0.20M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider’s post-transaction holdings but does not introduce new company fundamentals.
Market read
A director’s scheduled sale under 10b5-1 is generally low-signal for price action absent other catalysts.
What to watch
Traders may over-weight insider sales; without accompanying buys, guidance changes, or clinical/regulatory updates, the signal is typically weak.
Background
This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc.
Ticker impact
Guardant Health director POTTER MYRTLE S sold 1,556 shares on 2026-06-22 for $131.16/share under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless paired with other new company-specific catalysts.
The filing is a standard director sale with a stated 10b5-1 plan, and the article provides no new operational, financial, or regulatory development for GH.
Market effects
No meaningful read-across to biotech/diagnostics sector fundamentals from a single director sale.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.
Key entities
- issuerGuardant Health, Inc.
Subject of the Form 4 insider transaction disclosure (GH).
- insiderPOTTER MYRTLE S
Director who executed an open-market sale under a pre-arranged 10b5-1 plan.
